{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T08:02:23Z","timestamp":1775721743329,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI radiopharm. chem."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Platelet-derived growth factor receptor\u2013\u03b2 (PDGFR\u03b2) is a canonical marker of pericytes and stromal cells in most tissues. It is present on cancer associated fibroblasts (CAFs) in the tumor microenvironment and has thus been proposed as a potential therapeutic target both for anti-cancer drugs as well as for radioligand therapy (RLT). ATH001 is a novel Affibody molecule-based radiopharmaceutical in clinical development for targeting of PDGFR\u03b2. We hypothesize that dimerization of ATH001 could improve affinity to PDGFR\u03b2, leading to better characteristics for in vivo targeting. The dimeric construct, named ATH022, was generated by conjugation of two chemically synthesized ATH001 binders to a tri-functional linker comprising a DOTA chelator. Here, we present a comprehensive in vitro and in vivo evaluation of Gallium-68 and Indium-111 labeled ATH022, in direct comparison with ATH001.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>DOTA-ATH022 acted as a PDGFR\u03b2 antagonist and competed dose-dependently with the endogenous ligand PDGF-BB. Affinity of the dimer was improved approximately tenfold compared to DOTA-ATH001, mainly due to strongly decreased off-rate. Radiolabeled DOTA-ATH022 demonstrated higher specific binding and longer retention to U87 cells in vitro. Radiolabeled DOTA-ATH022 also exhibited elevated binding in PDGFR\u03b2-positive tissues spleen and U87 tumors, that could be blocked by ATH001 in excess. Binding of DOTA-ATH022 in PDGFR\u03b2 avid and well-perfused spleen was 3 times higher than for DOTA-ATH001, but tumor binding was lower. In vivo retention in spleen was 5 times longer for Indium-111 labeled ATH022, in agreement with its in vitro binding characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>DOTA-ATH022 is a novel dimerized version of ATH001, with significantly improved affinity towards PDGFR\u03b2. Retention of radiolabeled DOTA-ATH022 in PDGFR\u03b2-avid tissues and tumors was increased, however uptake in solid tumor tissue was not improved.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41181-026-00439-x","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T18:25:03Z","timestamp":1773685503000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Increased affinity by dimerization of radiolabeled Affibody molecule ATH001 targeting PDGFR\u03b2"],"prefix":"10.1186","volume":"11","author":[{"given":"Ayman","family":"Abouzayed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo","family":"Olsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bogdan","family":"Mitran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hemantha","family":"Mallapura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tahmida","family":"Akter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Velikyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olle","family":"Korsgren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl-Henrik","family":"Heldin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"L\u00f6fblom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2515-8790","authenticated-orcid":false,"given":"Olof","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"439_CR1","first-page":"485","volume":"58","author":"GP Adams","year":"1998","unstructured":"Adams GP, Schier R, Marshall K, Wolf EJ, Mccall AM, Marks JD, et al. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res. 1998;58:485\u201390.","journal-title":"Cancer Res"},{"issue":"1","key":"439_CR2","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.1038\/s41467-023-39762-1","volume":"14","author":"L Cords","year":"2023","unstructured":"Cords L, Tietscher S, Anzeneder T, Langwieder C, Rees M, de Souza N, et al. Cancer-associated fibroblast classification in single-cell and spatial proteomics data. Nat Commun. 2023;14(1):4294.","journal-title":"Nat Commun"},{"key":"439_CR3","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1002\/ijc.22999","volume":"121","author":"Y Hasumi","year":"2007","unstructured":"Hasumi Y, K\u0142osowska-Wardega A, Furuhashi M, Ostman A, Heldin CH, Hellberg C. Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling. Int J Cancer. 2007;121:2606\u201314.","journal-title":"Int J Cancer"},{"issue":"4","key":"439_CR4","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1152\/physrev.1999.79.4.1283","volume":"79","author":"CH Heldin","year":"1999","unstructured":"Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 1999;79(4):1283\u2013316. https:\/\/doi.org\/10.1152\/physrev.1999.79.4.1283.","journal-title":"Physiol Rev"},{"key":"439_CR5","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/nrc1456","volume":"4","author":"C-H Heldin","year":"2004","unstructured":"Heldin C-H, Rubin K, Pietras K, \u00d6stman A. High interstitial fluid pressure\u2014an obstacle in cancer therapy. Nat Rev Cancer. 2004;4:806\u201313. https:\/\/doi.org\/10.1038\/nrc1456.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"439_CR6","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jmb.2011.01.033","volume":"407","author":"M Lindborg","year":"2011","unstructured":"Lindborg M, Cortez E, H\u00f6id\u00e9n-Guthenberg I, et al. Engineered high-affinity affibody molecules targeting platelet-derived growth factor receptor \u03b2 in vivo. J Mol Biol. 2011;407(2):298\u2013315. https:\/\/doi.org\/10.1016\/j.jmb.2011.01.033.","journal-title":"J Mol Biol"},{"issue":"10","key":"439_CR7","doi-asserted-by":"publisher","first-page":"9243","DOI":"10.1021\/acsnano.6b02776","volume":"10","author":"L Miao","year":"2016","unstructured":"Miao L, Newby JM, Lin CM, Zhang L, Xu F, Kim WY, et al. The binding site barrier elicited by tumor-associated fibroblasts interferes disposition of nanoparticles in stroma-vessel type tumors. ACS Nano. 2016;10(10):9243\u201358. https:\/\/doi.org\/10.1021\/acsnano.6b02776.","journal-title":"ACS Nano"},{"issue":"2","key":"439_CR8","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3892\/ijo.2011.1045","volume":"39","author":"OF Qvarnstr\u00f6m","year":"2011","unstructured":"Qvarnstr\u00f6m OF, Simonsson M, Carlsson J, Tran TA. Effects of affinity on binding of HER2-targeting Affibody molecules: model experiments in breast cancer spheroids. Int J Oncol. 2011;39(2):353\u20139. https:\/\/doi.org\/10.3892\/ijo.2011.1045.","journal-title":"Int J Oncol"},{"key":"439_CR9","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1158\/1535-7163.MCT-09-0195","volume":"8","author":"MM Schmidt","year":"2009","unstructured":"Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther. 2009;8:2861\u201371. https:\/\/doi.org\/10.1158\/1535-7163.MCT-09-0195.","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"439_CR10","doi-asserted-by":"publisher","first-page":"102104","DOI":"10.1016\/j.isci.2021.102104","volume":"24","author":"Y Song","year":"2021","unstructured":"Song Y, Jeong H, Kim SR, Ryu Y, Baek J, Kwon J, et al. Dissecting the impact of target-binding kinetics of protein binders on tumor localization. iScience. 2021;24(2):102104. https:\/\/doi.org\/10.1016\/j.isci.2021.102104.","journal-title":"iScience"},{"issue":"12","key":"439_CR11","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.3390\/ph18121833","volume":"18","author":"I Velikyan","year":"2025","unstructured":"Velikyan I, Grinnemo KH, Flodin V, James S, Wagner M, Thelander U, et al. Ga-68 labelled Affibody molecule based radiopharmaceutical targeting platelet derived growth factor receptor beta for detection of active fibrosis in patients with myocardial infarction. Pharmaceuticals. 2025;18(12):1833. https:\/\/doi.org\/10.3390\/ph18121833.","journal-title":"Pharmaceuticals"},{"issue":"1","key":"439_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s41181-023-00210-6","volume":"8","author":"O Wegrzyniak","year":"2023","unstructured":"Wegrzyniak O, Zhang B, Rokka J, et al. Imaging of fibrogenesis in the liver by [18F]TZ-Z09591, an Affibody molecule targeting platelet derived growth factor receptor \u03b2. EJNMMI Radiopharm Chem. 2023;8(1):23. https:\/\/doi.org\/10.1186\/s41181-023-00210-6.","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"5","key":"439_CR13","doi-asserted-by":"publisher","first-page":"109688","DOI":"10.1016\/j.isci.2024.109688","volume":"27","author":"O Wegrzyniak","year":"2024","unstructured":"Wegrzyniak O, Lechi F, Mitran B, et al. Non-invasive PET imaging of liver fibrogenesis using a RESCA-conjugated Affibody molecule. iScience. 2024;27(5):109688. https:\/\/doi.org\/10.1016\/j.isci.2024.109688.","journal-title":"iScience"},{"issue":"1","key":"439_CR14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s41181-025-00366-3","volume":"10","author":"O Wegrzyniak","year":"2025","unstructured":"Wegrzyniak O, Lechi F, Rokka J, Mitran B, Zhang B, Thelander U, et al. PET imaging of platelet derived growth factor receptor \u03b2 in lung fibrosis. EJNMMI Radiopharm Chem. 2025;10(1):44. https:\/\/doi.org\/10.1186\/s41181-025-00366-3.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"439_CR15","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.3389\/fimmu.2017.01287","volume":"8","author":"KT Xenaki","year":"2017","unstructured":"Xenaki KT, Oliveira S, van Bergen En Henegouwen PMP. Antibody or antibody fragments: Implications for molecular imaging and targeted therapy of solid tumors. Front Immunol. 2017;8:1287. https:\/\/doi.org\/10.3389\/fimmu.2017.01287.","journal-title":"Front Immunol"},{"issue":"1","key":"439_CR16","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s41181-025-00410-2","volume":"10","author":"CN Yashaswini","year":"2025","unstructured":"Yashaswini CN, Mitran B, Papadopoulos N, Wegrzyniak O, L\u00f6fblom J, Nordstr\u00f6m H, et al. PDGFR\u00df targeted positron emission tomography as a non-invasive biomarker for activated hepatic stellate cells: last steps before clinical translation. EJNMMI Radiopharm Chem. 2025;10(1):80. https:\/\/doi.org\/10.1186\/s41181-025-00410-2.","journal-title":"EJNMMI Radiopharm Chem"}],"container-title":["EJNMMI Radiopharmacy and Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41181-026-00439-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-026-00439-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-026-00439-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T07:29:31Z","timestamp":1775719771000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41181-026-00439-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["439"],"URL":"https:\/\/doi.org\/10.1186\/s41181-026-00439-x","relation":{},"ISSN":["2365-421X"],"issn-type":[{"value":"2365-421X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"assertion":[{"value":"15 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the performed procedures were in accordance with the ARRIVE guidelines for animal research. The animal experiments were ethically reviewed, authorized by the Animal Ethics Committee of the Swedish Animal Welfare Agency and carried out in accordance with the European Directive 2010\/63\/EEC and the institutional guidelines at Uppsala University (UFV 2007\/724).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AA and OE are employees of Antaros Tracer AB. BM was an employee of Antaros Tracer AB at the time of performing the study. OE is listed as inventor of a patent concerning PDGFR\u03b2 binding peptides. The remaining authors declare that they have no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}